Bispecific antibodies (BsAbs) are a major advancement in therapeutic oncology and hematology, capable of simultaneously engaging two distinct targets. This ...
Celltrion targets innovative drug development with new ADC and antibody candidates Celltrion aims for growth by venturing ...
Korea’s top biopharmaceutical firms, Celltrion and Samsung Biologics, envisioned their future strategies for expansion at J.P ...
The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...
Invenra has launched its Rapid Antibody Discovery Service, designed to simplify and de-risk the preclinical development of ...
Pharmaceutical Technology on MSN1d
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5mAdditionally, Daiichi Sankyo has partnered with MSD in a $22bn deal to advance ADCs targeting HER3, B7-H3, and CDH6. Each therapy in this pipeline utilises Daiichi Sankyo’s DXd technology. Enhertu and ...
NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE: BHVN) and Merus N.V.
To identify this year’s Drugs to Watch 2025 list, Clarivate drew from expertise from over 160 Clarivate analysts covering ...
The FDA has granted BTD to GSK’22, a B7-H3-targeted antibody-drug conjugate, for the treatment of adult patients with ...
Transforming the landscape of drug discovery with next-gen capabilities in obesity research, small molecule and antibody design, antibody-drug conjugate development, and interactive AI AlpaMeld Logo ...
Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback